Multi-omics Characteristics and Prognosis of Idiopathic Sudden Sensorineural Hearing Loss
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age4-65
SponsorDan Bing
About this trial
The goal of this observational study is to describe the multi-omics characteristics and to learn about the prognostic factors in patients with idiopathic sudden sensorineural hearing loss (SSNHL). The main problems it aims to deal with are:
* if there is a difference in data of exome and targeted sequencing among patients with SSNHL affecting bilateral and unilateral sides, and healthy controls * if there is a difference in the parameter of MRI among patients with SSNHL affecting bilateral and unilateral sides, and healthy controls * to find out which factor from multi-omics data relates to outcomes of SSNHL * to develop the best prognostics model based on the multi-omics data.
Participants will be received audiological tests, blood specimen collection and radiological examination. Researchers will explore the relationship between the multi-omics data and the prognosis and develop the predictive model.
Eligibility criteria
Qualifiers
Age ≥ 4
Participants with SSNHL: unilateral or bilateral sensorineural hearing loss of > 30 dB HL (decibel) involving at least 3 continuous test frequencies developing within 72 hours
Healthy controls: people with PTA thresholds of all test frequencies ≤ 20 dB HL and without otologic disease in the last 3 months
Completed informed consent and promised to finish follow-ups
Disqualifiers
Hearing loss with explicit causes, including noise-induced, Ménière's disease, ototoxicity exposure, mumps infection or history of syphilis infection and so on.
A history of head trauma or otologic surgery.
Malformation of temporal bone discovered by computed tomography (CT)
Retro-cochlear lesion discovered by magnetic resonance imaging (MRI)
Trial design
Treatments tested in this trial
- Not listed
Trial groups
400 Participants
are grouped into 3 trial groupsLocations
Sponsors and collaborators
Dan Bing
Lead sponsor
Tongji Hospital
Sponsor institution
Source ClinicalTrials.gov